Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723219 | 0.83 | MEN1 (0.45) | KMT2AALDH1A1MEN1RAB9ANPC1 | |
| SCHEMBL12723738 | 0.83 | CA12 (0.50) | KMT2AALDH1A1MEN1RAB9ANPC1 | |
| SCHEMBL2442592 | 0.77 | NPC1 (0.69) | KMT2AALDH1A1MEN1RAB9ANPC1 | |
| SCHEMBL4222200 | 0.76 | — | — | |
| SCHEMBL16762905 | 0.74 | MAPT (0.54) | KMT2AALDH1A1MEN1NPC1HTT | |
| SCHEMBL27848838 | 0.72 | KMT2A (0.77) | CHEK1PIM1MAPK8CLK4KMT2A | |
| SCHEMBL2434971 | 0.72 | NPC1 (0.61) | KMT2AALDH1A1RAB9ANPC1LMNA | |
| SCHEMBL10026584 | 0.72 | CHEK1 (1.00) | CHEK1PIM1MAPK8CLK4KMT2A | |
| SCHEMBL14955188 | 0.72 | RAB9A (0.63) | KMT2AALDH1A1MEN1RAB9ANPC1 | |
| SCHEMBL8671118 | 0.70 | KMT2A (0.68) | CHEK1PIM1MAPK8CLK4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583535-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2023-02-21 | — | — | US | disclosed |
| US-20210244741-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-10786510-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2020-09-29 | — | — | US | disclosed |
| US-10695353-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2020-06-30 | — | — | US | disclosed |
| EP-3485883-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OccuRx Pty Ltd (AU) | 2019-05-22 | — | — | EP | disclosed |
| EP-2947073-B1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2019-04-03 | — | — | EP | disclosed |
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-9951087-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-04-24 | — | — | US | disclosed |
| US-9839640-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2017-12-12 | — | — | US | disclosed |
| EP-2947073-A2 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics Pty Ltd (AU) | 2015-11-25 | — | — | EP | disclosed |
| US-20150266893-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-09-24 | — | — | US | disclosed |
| US-9062076-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-06-23 | — | — | US | disclosed |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-10-25 | — | — | US | disclosed |
| WO-2012068612-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266893-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | CHEK1 3510/4885PIM1 3442/4885MAPK8 2848/4885 |
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | CHEK1 4218/4885PIM1 2500/4885MAPK8 3025/4885 |
| US-20210244741-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | CHEK1 4218/4885PIM1 2500/4885MAPK8 3025/4885 |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | CHEK1 3510/4885PIM1 3442/4885MAPK8 2848/4885 |
| US-10695353-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | CHEK1 4218/4885PIM1 2500/4885MAPK8 3025/4885 |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | CHEK1 4218/4885PIM1 2500/4885MAPK8 3025/4885 |
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | CHEK1 4218/4885PIM1 2500/4885MAPK8 3025/4885 |
| US-11583535-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | CHEK1 4218/4885PIM1 2500/4885MAPK8 3025/4885 |
| US-10786510-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | CHEK1 4218/4885PIM1 2500/4885MAPK8 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.